摘要
目的:探索氢氧化镁对BSA微球体外释放的影响,优化BSA微球的制备工艺。方法:通过水包油包固复乳法制备BSA-PLGA微球。先将BSA与葡聚糖制备成玻璃体颗粒,再将玻璃体颗粒与氢氧化镁包裹进PLGA中,制备成缓释微球。在扫描电镜下观察其形态。然后用Micro BCA法测定其包封率和载药量,并考察其体外释放行为。结果:所制得的微球粒径约60μm,呈较好的球形。添加氢氧化镁后,BSA微球的包封率和载药量都有显著提高。不同含量的氢氧化镁对BSA微球的包封率和载药量影响也不同。在体外释放过程中,载有氢氧化镁的微球14天累积释放量为(85.10±2.67)%,而对照组不到80%。结论:通过调整氢氧化镁的量,可以制得形态完整,大小均匀,突释较小的BSA微球。
Objective： To adjust the release rates of BSA-PLGA microspheres by encapsulating Mg（OH）2. Methods： BSA-loaded Mg（OH）2nanoparticles were microencapsulated in PLGA microspheres using a solid-in-oil-in-water（S/O/W） double emulsion solvent evaporation technique. Firstly the Vitreous paticles was prepared by BSA and Dextran. Then the paticles and Mg（OH）2were encapsulated in PLGA microspheres. The BSA microspheres were analyzed by SEM and the encapsulation efficiency were measured. In vitro release profiles of the BSA microspheres were detected by Micro BCA. Results： The particle is about 60μm and possessed well spherical shape.The encapsulation efficiency and vitro release profiles was increased with adding different concentration of Mg（OH）2. During 14 days,the cumulative release risperidone from microspheres with Mg（OH）2was（85.10±2.67）%, but the control was not up to 80%. Conclusion： The BSA microspheres with proper particle size and low burst release amount were prepared by controlling Mg（OH）2.
出处
《现代生物医学进展》
CAS
2016年第23期4431-4433,4414,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(81373366)
上海交通大学医工交叉项目(YG2013MS52
YG2013MS62)
